Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis by Tournadre, Anne et al.
Changes in body composition and metabolic profile
during interleukin 6 inhibition in rheumatoid arthritis
Anne Tournadre1,2*, Bruno Pereira3, Fréderic Dutheil4,5,6, Charlotte Giraud1, Daniel Courteix5,6, Vincent Sapin7,8,
Thomas Frayssac1, Sylvain Mathieu1, Sandrine Malochet-Guinamand1 & Martin Soubrier1,2
1Rheumatology Department, CHU Clermont-Ferrand, 58 rue Montalembert, BP 69, 63003, Clermont-Ferrand CEDEX, France; 2UNH-UMR 1019, INRA, University Clermont
Auvergne, 58 rue Montalembert, BP 321, 63009, Clermont-Ferrand CEDEX, France; 3Biostatistics Unit (DRCI), CHU Clermont-Ferrand, 58 rue Montalembert, BP 69, 63003,
Clermont-Ferrand CEDEX, France; 4Department of Preventive and Occupational Medicine, CHU Clermont-Ferrand, 58 rue Montalembert, BP 69, 63003, Clermont-Ferrand
CEDEX, France; 5Laboratory of Metabolic Adaptations to Exercise in Physiological and Pathological Conditions EA3533, University Clermont Auvergne, CNRS LaPSCo,
Physiological and Psychosocial Stress, 24 Avenue des Landais, 63171, Aubière, France; 6Faculty of Health, Australian Catholic University, Melbourne, Victoria, Australia;
7Biochemistry and Molecular Biology Department, CHU Clermont-Ferrand, 58 rue Montalembert, BP 69, 63003, Clermont-Ferrand CEDEX, France; 8University Clermont
Auvergne, EA7281, 28 Place Henri-Dunant, 63001, Clermont-Ferrand, France
Abstract
Background Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by increased mortality associated
with cardiometabolic disorders including dyslipidaemia, insulin resistance, and cachectic obesity. Tumour necrosis factor
inhibitors and interleukin 6 receptor blocker licensed for the treatment of RA decrease inflammation and could thus improve
cardiovascular risk, but their effects on body composition and metabolic profile need to be clarified. We investigated the
effects of tocilizumab (TCZ), a humanized anti-interleukin 6 receptor antibody, on body composition and metabolic profile
in patients treated for RA.
Methods Twenty-one active RA patients treated with TCZ were included in a 1 year open follow-up study. Waist circumference,
body mass index, blood pressure, lipid profile, fasting glucose, insulin, serum levels of adipokines and pancreatic/gastrointestinal hor-
mones, and body composition (dual-energy X-ray absorptiometry) were measured at baseline and 6 and 12 months of treatment. At
baseline, RA patients were compared with 21 non-RA controls matched for age, sex, body mass index, and metabolic syndrome.
Results Compared with controls, body composition was altered in RA with a decrease in total and appendicular lean mass,
whereas fat composition was not modified. Among RA patients, 28.6% had a skeletal muscle mass index below the cut-off
point for sarcopaenia (4.8% of controls). After 1 year of treatment with TCZ, there was a significant weight gain without
changes for fat mass. In contrast, an increase in lean mass was observed with a significant gain in appendicular lean mass
and skeletal muscle mass index between 6 and 12 months. Distribution of the fat was modified with a decrease in
trunk/peripheral fat ratio and an increase in subcutaneous adipose tissue. No changes for waist circumference, blood
pressure, fasting glucose, and atherogenic index were observed.
Conclusions Despite weight gain during treatment with TCZ, no increase in fat but a modification in fat distribution was
observed. In contrast, muscle gain suggests that blocking IL-6 might be efficient in treating sarcopaenia associated with RA.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory disease
characterized by progressive joint destruction, disability, and
premature death with an increased cardiovascular mortality.1
In addition to traditional cardiovascular risk factors, systemic
inflammation and metabolic disorders including insulin
resistance, dyslipidaemia, and cachectic obesity2,3 contribute
to this excess of cardiovascular risk and mortality. Among
patients with RA, low body mass index (BMI) is associated
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with cardiovascular death which could be related to cachexia-
associated metabolic disorders.4 Sarcopaenia is defined by
both low muscle mass and muscle function (strength or per-
formance) with a risk of physical disability, poor quality of
life, and death.5,6 During ageing and chronic diseases,
decrease in lean mass is frequently associated with pre-
served or even increased body fat, notably ectopic fat in
the muscles, regardless of changes in total body weight,
thus defining sarcopaenic obesity. Sarcopaenic obesity
implies a close link between adipose tissue and muscle. This
new phenotype combines the risks arising from changes in
muscle mass, limiting mobility and participating in the
appearance of metabolic disorders, and from excess adipos-
ity which generates significant adverse health effects (hyper-
tension, dyslipidaemia, cardiovascular risk, and insulin
resistance). The loss of muscle is associated with intramus-
cular or ectopic fat infiltration and increase in total and/or
visceral adipose tissue responsible for the production of
adipocytokines as well as lipotoxicity, mitochondrial dysfunc-
tion, oxidative stress, insulin resistance, and anabolic resis-
tance. In turn, these disturbances exacerbate sarcopaenia,
leading to a decrease in physical activity and resting energy
expenditure in a self-contained loop. In RA, conventional
disease-modifying antirheumatic drugs (DMARDs) and bio-
logics targeting pro-inflammatory cytokines decrease inflam-
mation and could thus improve cardiovascular risk. Cytokine
inhibitors may also be a potential therapeutic approach for
sarcopaenia as tumour necrosis factor (TNF) α and
interleukin 6 (IL-6) are known to play a key role in muscle
proteolysis, mitochondrial muscle dysfunction, and insulin
resistance. However, body weight gain both with TNF inhib-
itors and IL-6 receptor (IL-6R) blocker has been reported in
RA patients,7–10 and its effect on body composition and car-
diometabolic profile needs to be clarified.11–14 With TNF
blockers, two randomized trials in RA did not show any differ-
ences for body composition after 6 months and 1 year of
treatment.11,14 However, an increased in fat mass with
preservation of muscle mass was observed with infliximab
during long-term therapy (2 years).14 The most commonly
diagnosis tool used to assess body composition is the dual-
energy X-ray absorptiometry (DXA). DXA allows distinguishing
both lean and fat mass composition and identifying changes in
the body fat distribution, android adiposity and visceral
abdominal fat being the most associated with cardiometa-
bolic disorders. To analyse the effect of IL-6 inhibition on
body composition in patients with active RA treated with
tocilizumab (TCZ), a humanized anti-IL-6R antibody directed
to the IL-6Rα chain licensed for the treatment of RA, we con-
ducted a 1 year open follow-up study. Changes in lean and fat
mass were assessed at 6 and 12 months of treatment with
DXA and compared at baseline to 21 non-RA matched con-
trols. In addition, metabolic profile, serum levels of




Twenty-one consecutive patients with active RA and
starting new treatment with TCZ were included between
June 2011 and January 2013 in an open, prospective 1 year
follow-up study. The patients fulfilled the 2010 RA classifi-
cation criteria15 and had active disease as defined by dis-
ease activity score in 28 joints (DAS28) >3.2. The study
was approved by the local ethics committee (Institutional
Review Boards: 00008526). All patients received verbal
and written information and signed a consent form prior
to inclusion. Longitudinal data were available for 21 RA pa-
tients at baseline, 15 patients at 6 months, and 11 at 1 year
of follow-up.
Controls
For baseline references, data were obtained from 21 non-
RA controls recruited in the Reverse Metabolic Syndrome
by Lifestyle and Various Exercises trial between May 2009
and October 201116 and matched with RA patients for
age, sex, BMI, and criteria of metabolic syndrome. Briefly,
patients with metabolic syndrome had a sedentary lifestyle,
stable body weight, and medication over the previous
6 months. They had no chronic diseases except those defin-
ing metabolic syndrome, no medications altering body
weight, and no restricted diet in the previous year. Healthy
participants had none of the defined criteria of metabolic
syndrome, no chronic disease, no routine medication, un-
changed lifestyle over the previous 12 months, and less
than 3 h per week of physical activity. For matching, BMI
was categorized as <25 Kg/m2, 25–30 Kg/m2, and
>30 Kg/m2. Metabolic syndrome was defined according
the new WHO criteria.17
Measurements
Patient disease assessment
Demographic, disease, and clinical characteristics were
assessed at baseline and 6 and 12 months post treatment.
Disease duration, smoking, rheumatoid factor, anti-cyclic
citrullinated peptide antibodies, DAS28 using erythrocyte
sedimentation rate, European League Against Rheumatism
(EULAR) response, erosion on radiographs, current and past
use of glucocorticoids, and biologic and non-biologic
DMARDs were recorded.
Body composition
All subjects underwent total body DXA scanning (HOLOGIC
Discovery A S/N 85701). Fat, lean, and bone masses for the
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total body and per region (arms, legs, and trunk) were
measured and analysed by using the manufacturer’s vali-
dated software (version 4.02 HOLOGIC APEX). Daily quality
control and calibration procedures were performed by using
the manufacturer’s standard.
Body fat percentage was calculated as the proportion of
total fat mass to total mass. Appendicular fat and lean
masses were computed as the sum of the tissue compart-
ment (fat or lean) of both arms and legs. Skeletal muscle
mass index (SMI) was calculated as appendicular lean mass
divided by height (m)2, fat mass index as total fat mass di-
vided by height (m)2, and fat-free mass index as total body
mass without total fat mass divided by height (m)2. The
trunk-peripheral fat ratio, a measure of ‘android’ fat, was
calculated by using fat of the body trunk divided by the pe-
ripheral (legs and arms) fat. Separation of subcutaneous
adipose tissue (SAT) and visceral adipose tissue (VAT) was
performed by two blinded readers (SMG and CG) inside a
region of interest by using a new software developed on
DXA with a validated method.18,19 Lin’s concordance corre-
lation coefficient for the inter-reader concordance was 0.96
for VAT and 0.99 for SAT. The ratio of VAT area/SAT area
was calculated. An SMI lower than two SDs below the
mean SMI of young male and female reference groups
was defined as the gender-specific cut point for
sarcopaenia (Baumgartner’s criteria: men 7.26 kg/m2,
women 5.5 kg/m2).5
Cardiometabolic profile
Weight, height, waist circumferences, blood pressure, and
information on cholesterol-lowering, antihypertensive,
antidiabetic drugs were obtained from all patients. BMI was
calculated as weight (kg) divided by height (m2). Fasting
glucose and lipid profile [total cholesterol, low-density lipo-
protein cholesterol, high-density lipoprotein (HDL) choles-
terol, and triglycerides] were measured. The atherogenic
index (total cholesterol/HDL cholesterol) was then calculated.
Serum levels of adipokines and pancreatic/gastrointestinal
hormones were available for 15 patients at baseline and for
10 patients after 6 months of treatment. Adiponectin, leptin,
chemerin, visfatin, and resistin were assayed by enzyme-
linked immunosorbent assay with commercial kits
(Biovendor, Brno, Czech Republic). Insulin, ghrelin, amylin, C
peptide, gastric inhibitory polypeptide, glucagon-like
peptide-1, pancreatic polypeptide, and peptide tyrosine tyro-
sine were measured with luminex bead-based multiplex as-
say (Milliplex kit, Merck Millipore KGaA, Darmstadt,
Germany). Insulin resistance was assessed by using the ho-
meostatic model homeostatic model assessment for insulin
resistance [(insulin [mU/L] × glucose [mmoles/L]) ÷ 22.5]20
for 14 patients at baseline and 9 patients at 6 months, after
exclusion of one patient with uncontrolled hyperglycaemia.
Data were not available at 12 months.
Statistical analysis
The sample size was determined according to simulations on
effect size. For a two-sided type error of 5%, a statistical power
equal to 90%, and a correlation coefficient of 0.50 (paired con-
text), n = 13 patients (at M6) were necessary to highlight an ef-
fect size equals 1. For the same assumptions, n = 10 (at M12)
allowed a statistical power equals 80%. Statistical analysis was
performed by using Stata 13 software (StataCorp LP, College
Station, TX, US). The tests were two-sided, with a type I error
set at α = 0.05. The results were presented as mean (±SD) or
median (interquartile range) for continuous data and as the
number of patients and associated percentages for categorical
parameters. Comparisons between the independent groups
were performed by using the chi-squared or Fisher’s exact tests
for categorical variables and Student’s t-test or Mann–Whitney
test for quantitative parameters. The relationship between
quantitative outcomes was studied with correlation coeffi-
cients. Considering the several multiple comparisons, an infla-
tion of the type I error was applied (Sidak’s correction).
Repeated data were compared by using mixed models to take
into account within-subject and between-subject variabilities
(patient as random effect). All the individual P-values were re-
ported without systematic mathematical correction for distinct
tests.21 Sensitivity analyses investigated the impact of the miss-
ing data on the results. In order to assess the issue of missing
data, the estimation methods developed by Verbeke and
Molenberg22 were considered. A particular focus was given to
the magnitude of difference and to the clinical relevance.23
Available-case analysis on completers (longitudinal analysis
for the 11 patients who had data at baseline, 6 months, and
1 year) and comparison of baseline characteristics between
the 11 patients which have completed the study at 1 year (com-
pleters) and the 10 patients for which data were missing (non-
completers) were performed. All statistical analyses were per-
formed by the biostatistics unit (DRCI) of the University Hospi-
tal of Clermont-Ferrand (B. Pereira, PhD Biostatistics).
Results
Baseline characteristics of rheumatoid arthritis
patients and matched non-rheumatoid arthritis
controls
The baseline characteristics of 21 RA patients and 21
matched non-RA controls are shown in Table 1. Patients with
RA received more cholesterol-lowering drug, and the athero-
genic index was lower. During the follow-up, the proportion
of RA patients with cholesterol-lowering drug did not signifi-
cantly change from baseline (73% at 6 and 12 months). Four-
teen patients in the RA group were currently receiving
steroids, while none in the control group. The number of
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RA patients on steroids and the mean steroid dosage did not
change during the follow-up. Eighteen RA patients (86%) had
previously received at least one biologic. The mean baseline
DAS28 decreased significantly at 6 and 12 months
(2.92 ± 0.8 and 2.8 ± 1.5, respectively, P < 0.001).
Comparison of rheumatoid arthritis patient body
composition with matched non-rheumatoid
arthritis controls
The baseline body composition of RA patients and controls is
shown in Table 2. Compared with controls, RA patients had sig-
nificantly lower total and appendicular lean mass at baseline.
The SMI was not significantly decreased because the height
was higher in non-RA controls (1.68 m vs 1.61 m, P = 0.02). In
the RA group, six patients (28.6%) had an SMI value below
the cut-off point for sarcopaenia, whereas only one control
(4.8%) had sarcopaenia defined in this way (P = 0.04). Mea-
sures of fat mass and distribution of the fat did not differ signif-
icantly between RA and controls. Among the six RA patients
with sarcopaenia as defined by an SMI value below the
gender-specific cut point for sarcopaenia (Baumgartner’s
criteria), four had also a BMI below 20 and would therefore
be considered cachectic. One other patient had a sarcopaenic
obesity defined on DXA by the association of an SMI below
the gender-specific cut point for sarcopaenia and a body fat
percentage above 27% for men and 38% for women.24 In
non-sarcopaenic RA patients, four had overfat defined on
DXA criteria24 and two had a BMI <20 without sarcopaenia.
Body composition changes of rheumatoid arthritis
patients during treatment with tocilizumab
Body composition changes at 6 and 12 months of follow-up are
presented in Table 3. After 1 year of treatment with TCZ, we ob-
served a significant weight and BMI gain without changes for fat
composition. In contrast, total lean mass and fat free mass index
increased at 1 year. There was a significant gain in appendicular
leanmass at 12months and both at 6 and 12months for the SMI
with a significant change between 6 and 12 months (P = 0.017).
Moreover, this increase in lean mass was associated with mod-
ification of the fat distribution. A decrease in trunk/peripheral fat
ratio and an increase in SATwere observed at 1 year, whereas VAT
did not change. The VAT/SAT ratio decreased at 1 year, but the dif-
ference was borderline significant (P = 0.07).
Disease characteristics at baseline (age, duration, smoking,
DAS28, radiographic erosion, past use of biologics or steroids,
Table 1 Baseline characteristics of the 21 patients with rheumatoid ar-
thritis treated with tocilizumab and 21 controls matched for age, sex,
body mass index, and criteria of metabolic syndrome [mean ± SD or num-
ber (%)]
RA (n = 21) Controls (n = 21)
Age, years 57.8 ± 10.5 57.8 ± 5.4
Gender, female 16/21 (76) 16/21 (76)
Body weight, Kg 61.8 ± 19.3 68.4 ± 15.0
BMI, Kg/m2 23.6 ± 6.7 24.6 ± 5.4
Waist circumference, cm 85.4 ± 13.6 83.6 ± 11.7
Metabolic syndrome 6/21 (28.5) 6/21 (28.5)
HOMA-IR
[(insulin × glucose) / 22.5]
2.35 ± 1.3 2.36 ± 1.3
Triglycerides, g/L 0.99 ± 0.45 1.16 ± 0.64
Total cholesterol, g/L 2.05 ± 0.43 2.25 ± 0.29
LDL cholesterol, g/L 1.26 ± 0.32 1.42 ± 0.25
HDL cholesterol, g/L 0.66 ± 0.20 0.6 ± 0.18
Total/HDL cholesterol 3.30 ± 1.02 4.07 ± 1.29*
Cholesterol-lowering drug
therapy
11/21 (52.4) 3/21 (14.3)**
Antihypertensive drug 6/21 (28.5) 4/21 (19)








Radiographic erosions 13/21 (62) —
DAS28 4.94 ± 1.25 —






Smoking 10/21 (48) NR
Concomitant DMARD 19/21 (90) —
Current steroids 14/21 (67) 0/21
Mean steroid dosage
(prednisone mg/d)
4.12 ± 3.35 —
At least one previous biologic 18/21 (86) —
BMI, body mass index; DAS28, disease activity score in 28 joints;
DMARD, disease-modifying antirheumatic drug; EULAR, European
League Against Rheumatism; HDL, high-density lipoprotein;
HOMA-IR, homeostatic model assessment for insulin resistance;




Table 2 Baseline body composition of rheumatoid arthritis patients
treated with tocilizumab and controls [mean ± SD or number (%)]
RA (n = 21)
Controls
(n = 21)
Total lean mass, Kg 42.1 ± 11.1* 47.5 ± 8.7
Appendicular lean mass, Kg 17.7 ± 5.4* 20.1 ± 3.9
Fat-free mass index (FFMI), Kg/m2 16.7 ± 3.0 17.6 ± 2.6
Skeletal muscle mass index
(SMI), Kg/m2
6.7 ± 1.4 7.1 ± 1
SMI cut-off points for
sarcopaenia (women ≤ 5.5 Kg/m2;
men ≤ 7.26 Kg/m2)
6/21 (28.6%)* 1/21 (4.8%)
Total fat mass, Kg 19.5 ± 12.3 19.7 ± 9.6
Body fat percentage, % 29.4 ± 9.8 27.5 ± 8.0
Fat mass index (FMI), Kg/m2 7.5 ± 4.8 7.0 ± 3.4
Trunk/peripheral fat ratio 0.77 ± 0.22 0.89 ± 0.25
Visceral adipose tissue (VAT), cm2 74.3 ± 43.1 108.9 ± 69.1
Subcutaneous adipose tissue
(SAT), cm2
241.3 ± 173.3 256.6 ± 123.7
VAT/SAT ratio 0.36 ± 0.21 0.43 ± 0.21
FFMI = lean mass + bone mineral content / height2; FMI = fat
mass / height2; SMI = appendicular (4 limbs) lean mass / height2.
*P < 0.05.
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and steroid dose) or EULAR response were not predictive of
changes in lean mass. No significant correlation between
baseline lean mass and EULAR response was observed. How-
ever, patients with a good–moderate EULAR response were
different in baseline fat composition compared with patients
without response. Baseline appendicular fat mass was higher
in patients with good–moderate EULAR response at 6 months
(9.8 ± 3.6 vs 6.5 ± 1.9 Kg, P = 0.03). Percentage of fat (32 ± 8%
vs 17 ± 5%, P = 0.03), appendicular fat mass (10.8 ± 4.3 vs
5.4 ± 0.2 Kg, P = 0.03), and fat mass index (8.45 ± 4.2 vs
3.7 ± 0.42, P = 0.03) were increased at baseline in patients
with a 12 month good–moderate EULAR response. This
Table 3 Body composition changes of patients with active rheumatoid arthritis treated with tocilizumab during 1 year follow-up with tocilizumab
treatment [mean ± SD or number (%)]
Baseline 6 months 1 year
Body weight, Kg 61.8 ± 19.3 60.9 ± 15.6 63.7 ± 16.1**
BMI, Kg/m2 23.6 ± 6.7 23.6 ± 5.2 24.8 ± 5.9**
Waist circumference, cm 85.4 ± 13.6 88.9 ± 14.6 91.7 ± 14.0
Total lean mass, Kg 42.1 ± 11.1 41.9 ± 11.8 43.2 ± 11.3*
Appendicular lean mass, Kg 17.7 ± 5.4 17.9 ± 5.3 18.7 ± 5.6***
Skeletal muscle mass index (SMI), Kg/m2 6.7 ± 1.4 6.9 ± 1.3* 7.2 ± 1.5***
Fat-free mass index (FFMI), Kg/m2 16.7 ± 3 16.9 ± 3 17.4 ± 3*
Total fat mass, Kg 19.5 ± 12.3 18.8 ± 8.6 19.5 ± 9.5
Body fat percentage, % 29.4 ± 9.8 29.6 ± 9.2 29.4 ± 8.8
Fat mass index (FMI), Kg/m2 7.5 ± 4.8 7.4 ± 3.8 7.8 ± 4.3
Trunk/peripheral fat ratio 0.77 ± 0.22 0.75 ± 0.16 0.70 ± 0.17***
Visceral adipose tissue (VAT), cm2 74.3 ± 43.1 76.6 ± 43.4 71.5 ± 33.7
Subcutaneous adipose tissue (SAT), cm2 241.3 ± 173.3 233.1 ± 134.3 263.9 ± 154.3**
VAT/SAT ratio 0.36 ± 0.21 0.34 ± 0.17 0.31 ± 0.19
FFMI = Lean mass + bone mineral content / height2; FMI = fat mass / height2; SMI = appendicular (4 limbs) lean mass / height2; trunk/




Table 4 Cardiovascular and metabolic changes in patients with active rheumatoid arthritis receiving tocilizumab during 1 year follow-up [mean ± SD or
number (%)]
Baseline 6 months 1 year
Systolic blood pressure, mmHg 123 ± 13 126 ± 14 125 ± 19
Systolic blood pressure ≥ 140 mmHg 3/20 (15) 3/15 (20) 4/10 (40)
Diastolic blood pressure, mmHg 72 ± 10 74 ± 10 71 ± 11
Diastolic blood pressure ≥ 90 mmHg 1/20 (5) 2/15 (13.3) 1/10 (10)
Total cholesterol, g/L 2.05 ± 0.43 2.24 ± 0.38* 1.86 ± 0.47
LDL cholesterol, g/L 1.26 ± 0.32 1.33 ± 0.39 1.01 ± 0.38
HDL cholesterol, g/L 0.66 ± 0.20 0.73 ± 0.23* 0.68 ± 0.21
Total/HDL cholesterol 3.30 ± 1.02 3.33 ± 1.23 2.87 ± 0.76
Fasting glucose, g/L 0.79 ± 0.16 0.97 ± 0.55 1.02 ± 0.37
Fasting glucose ≥ 1 g/L 3/21 (14.3) 3/13 (23.1) 2/10 (20)
Triglycerides, g/L 0.99 ± 0.45 0.99 ± 0.40 0.90 ± 0.35
C reactive protein level, mg/L median [IQR] 4.5 [2.9–31.1] 2.9 [1–2.9]** 1 [1–2.9]***
HOMA-IRa 2.1 ± 1.1 3.9 ± 5.1 NA
Adipokines
Adiponectin (μg/L) 20.2 ± 6.7 22.9 ± 5.1
Leptin (ng/L) 15.5 ± 17.2 13.3 ± 17*
Chemerin (ng/L) 52.1 ± 61.7 53.1 ± 69.7
Resistin (ng/L) 4.2 ± 1.4 4.1 ± 1.5
Visfatin (ng/L) 1.9 ± 2.9 1.7 ± 2
Ghrelin (active, pg/mL) 30.6 ± 23.3 23.0 ± 21.2
Amylin (pg/mL) 14.9 ± 7.7 18.3 ± 11.4
C peptide (pg/mL) 736 ± 359 934 ± 619
GIP (pg/mL) 54 ± 30 161 ± 192*
GLP-1 (active, pg/mL) 23.1 ± 31 20.3 ± 32
Pancreatic polypeptide (pg/mL) 120.6 ± 94.9 237.8 ± 260.7
PYY (pg/mL) 117.5 ± 126.0 143.3 ± 149.7
GIP, gastric inhibitory polypeptide; GLP-1, glucagon-like peptide-1; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assess-
ment for insulin resistance; IQR, interquartile; LDL, low-density lipoprotein; PYY, peptide tyrosine tyrosine.




Interleukin 6 inhibition in rheumatoid arthritis 643
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 639–646
DOI: 10.1002/jcsm.12189
correlation between baseline fat mass and EULAR response
may suggest that patients with less severe and refractory dis-
ease had more fat mass and less cachexia.
Cardiometabolic changes of rheumatoid arthritis
patients during treatment with tocilizumab
The results for cardiovascular and metabolic profiles are
shown in Table 4. During treatment with TCZ, no changes
for waist circumference, blood pressure, fasting glucose,
and triglycerides were observed. Total cholesterol and HDLc
increased significantly at 6 months of follow-up without mod-
ification of the atherogenic index. However, compared with
6 months of follow-up, total and LDL cholesterol levels as well
as atherogenic index significantly decreased after 1 year of
treatment (P = 0.007, P = 0.01, and P = 0.05, respectively). In-
sulin resistance was not modified at 6 months of follow-up.
Among adipokines, only serum levels of leptin were signifi-
cantly decreased at 6 months. The leptin/adiponectin ratio
used as a biomarker of cardiovascular risk25 decreased but
not significantly (0.76 ± 0.88 vs 0.58 ± 0.73, P = 0.08). The gas-
tric inhibitory polypeptide, an incretin secreted by gut in re-
sponse to feeding and involved in insulin secretion, was
increased after 6 months of treatment, whereas the second
incretin glucagon-like peptide-1 was not modified.
Sensitivity analysis
A comparison between the 11 patients who have completed
the study at 1 year and the 10 patients for which data were
missing did not show any significant differences for demo-
graphic, disease, and clinical characteristics (Table S1). Among
the 10 non-completers, the four patients for which the data
were missing between 6 and 12 months consisted of three
good–moderate EULAR responders and one non-responder at
6 months. The significant gain in lean mass was confirmed by
using available-case analysis in RA patients treated with TCZ
during 1 year of follow-up (Table S2). Compared with the full
data analysis, significant differences for the gain in weight
and leanmass persisted for fat-freemass index, total leanmass,
appendicular lean mass, and SMI. Body fat percentage de-
creased between 6 and 12 months. Consistent with the full
analysis, a redistribution of the fat towards peripheral and sub-
cutaneous compartments was noted after 1 year of follow-up.
Discussion
Our results confirm a decrease in muscle mass in RA pa-
tients compared with controls contrasting with normal fat
mass. We observed that almost one-third of RA patients
had a muscle mass below the cut-off value for sarcopaenia
defined by the European Working Group on Sarcopenia in
Older People (EWGSOP),5 contrasting with normal fat mass.
Moreover, for the majority of sarcopaenic patients, the de-
crease in lean mass was associated with a low BMI (<20)
supporting the evidence for rheumatoid cachexia in these
patients with active and refractory disease. Rheumatoid ca-
chexia, a complex metabolic syndrome, which associates
sarcopaenia with or without loss of fat mass, underlying ill-
ness, inflammation, insulin resistance, anorexia, and in-
creased breakdown of muscle proteins, was described
almost 100 years ago, and a number of studies reported ab-
normal body composition in RA patients.26 However, rheu-
matoid cachexia is under-recognized in clinical practice and
few recent data are available regarding the body composi-
tion of RA patients assessed with DXA, the most useful
and validated method, compared with controls.27,28 The fre-
quency of rheumatoid cachexia in the literature depends
upon the definition of cachexia and/or sarcopaenia, the
methods for assessing muscle mass, and the cut-off values. Al-
though the definition of sarcopaenia should include both low
muscle mass and low muscle function,5 a combination of the
two criteria was not reported in rheumatoid cachexia or
sarcopaenia studies. Cachexia was diagnosed in two-third of
patients by using anthropometric method,29 whereas Giles
et al. observed rates of sarcopaenia similar to ours (21.4% in
women with RA and 33.3% in men with RA) by using alterna-
tive SMI cut points for sarcopaenia without muscle function
assessment.28 The mechanisms responsible for muscle loss
have yet to be elucidated but could involve disease activity,
the reduced mobility, and corticosteroid treatment.6,30,31 In
turn, altered body composition is likely to impact health and
causes a cascade of cardiometabolic abnormalities.32,33
This first study of the impact of IL-6 inhibition on body
composition in RA shows a gain in weight likely to be re-
lated to a significant increase in muscle mass as no change
for fat mass was detected. To date, no specific therapeutic
strategy for rheumatoid cachexia has been defined. Avail-
able therapeutic methods include increasing physical activ-
ity with high-intensity resistance training34 and dietary
treatment, although most RA patients do not have deficien-
cies in protein or energy intake, resulting in a possible in-
crease in fat mass with cardiometabolic consequences.
Clinical management should then include the tight control
of systemic inflammation and RA activity. While cancer ca-
chexia could be improved with TCZ,35,36 the effect of
DMARDs on body composition in RA and on metabolic pro-
file needs to be further investigated to prove their efficacy
and safety.11–14 Weight and fat gain reported in many stud-
ies with TNF blockers or TCZ raises the question of their
cardiovascular and metabolic tolerance.7–10,12,14 In our
study, the cardiometabolic safety profile under treatment
appears to be favourable with a fat redistribution towards
peripheral and subcutaneous fat. The exact function of each
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adipokine in the context of chronic inflammation remains
uncertain.37 However, many authors consider leptin,
resistin, and visfatin as pro-inflammatory mediators,
whereas adiponectin can have pro-inflammatory or anti-
inflammatory properties depending on the isoform stud-
ied.38,39 Leptin, a key regulator of appetite, by inducing
the expression of anorexigenic factors and inhibiting the
production of orexigenic peptides, stimulates the produc-
tion of TNFα, IL-6, and IL-12. In turn, TNFα and IL1 up-
regulate leptin production.38 While elevated serum and
synovial fluid leptin levels were reported in RA,38 conven-
tional DMARDs and TNF blockers did not modify the levels
of leptin.38 Our results showing a significant decrease after
6 months on TCZ treatment might suggest a pro-
inflammatory IL-6 mediated effect of the leptin.
Several limitations to our study should be noted. Muscle
function, a key indicator of sarcopaenia using the EWGSOP
recommendation,5 was not assessed in our study. However,
a recent meta-analysis in a Brazilian population did not find
significant difference for the prevalence of sarcopaenia using
muscle mass and function criteria (EWGSOP) or muscle mass
alone (Baumgartner’s criteria).40 The low number of patients
and the missing data, though taken into account in the statis-
tic models, could be insufficient to exclude an effect of TCZ on
cardiometabolic profile. Moreover, the lack of control arm
does not allow concluding for a specific effect of IL-6 inhibition
on body composition. However, despite the low number of
patients, we were able to observe a significant change for all
the parameters of lean body mass with TCZ treatment. The
muscle gain observed at 1 year suggests that blocking IL-6
might be efficient in reversing muscle loss associated with
RA. These preliminary results need to be confirmed in larger
population and in randomized controlled study to compare
with conventional DMARDs and other biologics.
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